| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | NARS2 |
| Uniprot No | Q96I59 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 15-477aa |
| 氨基酸序列 | SSAPFP KHKPSAKLSV RDALGAQNAS GERIKIQGWI RSVRSQKEVL FLHVNDGSSL ESLQVVADSG LDSRELNFGS SVEVQGQLIK SPSKRQNVEL KAEKIKVIGN CDAKDFPIKY KERHPLEYLR QYPHFRCRTN VLGSILRIRS EATAAIHSFF KDSGFVHIHT PIITSNDSEG AGELFQLEPS GKLKVPEENF FNVPAFLTVS GQLHLEVMSG AFTQVFTFGP TFRAENSQSR RHLAEFYMIE AEISFVDSLQ DLMQVIEELF KATTMMVLSK CPEDVELCHK FIAPGQKDRL EHMLKNNFLI ISYTEAVEIL KQASQNFTFT PEWGADLRTE HEKYLVKHCG NIPVFVINYP LTLKPFYMRD NEDGPQHTVA AVDLLVPGVG ELFGGGLREE RYHFLEERLA RSGLTEVYQW YLDLRRFGSV PHGGFGMGFE RYLQCILGVD NIKDVIPFPR FPHSCLL |
| 预测分子量 | 54 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇关于NARS2重组蛋白的模拟参考文献示例(实际文献可能需要通过学术数据库检索确认)：
1. **《Structural and functional analysis of human mitochondrial NARS2》**
- 作者：Smith A, et al.
- 摘要：解析了NARS2重组蛋白的晶体结构，揭示了其与线粒体tRNA结合的关键结构域，并验证了致病突变对酶活性的影响。
2. **《NARS2 mutations impair mitochondrial translation and cause early-onset Leigh syndrome》**
- 作者：Johnson B, et al.
- 摘要：通过重组NARS2蛋白功能实验，证明其突变导致线粒体蛋白质合成障碍，与婴儿神经退行性疾病的关联机制。
3. **《Recombinant NARS2 expression rescues mitochondrial dysfunction in patient-derived fibroblasts》**
- 作者：Chen L, et al.
- 摘要：报道了利用重组NARS2蛋白在患者细胞中恢复线粒体功能，为基因治疗提供潜在策略。
---
**说明**：以上文献信息为模拟生成，实际研究中建议通过PubMed、Google Scholar等平台以关键词"NARS2 recombinant protein"或"NARS2 mitochondrial"检索最新文献。部分真实相关研究可能聚焦于NARS2的突变分析或疾病机制，重组蛋白的直接研究可能较少。
NARS2 (asparaginyl-tRNA synthetase 2) is a mitochondrial enzyme encoded by the nuclear *NARS2* gene, belonging to the class II family of aminoacyl-tRNA synthetases (aaRSs). It catalyzes the ATP-dependent attachment of L-asparagine to its cognate mitochondrial tRNA (tRNA^Asn), a critical step in mitochondrial protein synthesis. As a component of the mitochondrial translation machinery, NARS2 ensures the fidelity of mitochondrial DNA (mtDNA)-encoded protein production, which is essential for oxidative phosphorylation (OXPHOS) and cellular energy metabolism. Dysregulation of NARS2 has been linked to mitochondrial disorders, underscoring its role in maintaining mitochondrial homeostasis.
Recombinant NARS2 protein is engineered using heterologous expression systems (e.g., *E. coli* or mammalian cells) to produce purified, functional enzyme for research. This recombinant form retains the conserved catalytic domains, including the anticodon-binding region and the asparagine-specific active site, enabling in vitro studies of its structure-function relationships. Researchers utilize recombinant NARS2 to investigate pathogenic mutations (e.g., those associated with early-onset encephalopathy, hearing loss, or Leigh syndrome) and their effects on enzyme activity, tRNA recognition, and mitochondrial dysfunction. Additionally, it serves as a tool for screening potential therapeutics targeting aaRS-related mitochondrial diseases. The development of recombinant NARS2 has advanced our understanding of mitochondrial translation defects and their broader implications in neurodegeneration, metabolic syndromes, and aging-related pathologies. Its study also contributes to the growing field of mitochondrial medicine, aiming to address disorders rooted in OXPHOS failure.
×
